Oct 2026· International Journal of Molecular Sciences· Vol 27 21· 0 citations· 80 references
Medicine
TL;DR
The biological rationale for DC-directed immunotherapy, tumor-induced DC dysfunction, next-generation DC platforms, in vivo DC targeting, DC-derived extracellular vesicles, negative and controversial clinical evidence, and rational combinations with checkpoint blockade and tumor-microenvironment-modulating strategies are examined.
Abstract
Dendritic cells (DCs) are specialized antigen-presenting cells that shape antitumor immunity by integrating antigen uptake, processing, presentation, co-stimulation, and cytokine-mediated T-cell instruction. Their function is therefore critical for generating tumor-specific T-cell responses and may influence responsiveness to immune checkpoint inhibitors. Although early ex vivo DC vaccines established feasibility, safety, and immunogenicity, clinical efficacy has been heterogeneous. Sipuleucel-T demonstrated an overall-survival benefit in metastatic castration-resistant prostate cancer, whereas DCVax-L produced encouraging but methodologically debated survival signals in glioblastoma. More recently, individualized neoantigen mRNA vaccination combined with pembrolizumab has shown durable recurrence-free survival benefit in resected high-risk melanoma. This review examines the biological rationale for DC-directed immunotherapy, tumor-induced DC dysfunction, next-generation DC platforms, in vivo DC targeting, DC-derived extracellular vesicles, negative and controversial clinical evidence, and rational combinations with checkpoint blockade and tumor-microenvironment-modulating strategies. The field is evolving from the use of DCs as cellular vaccine vehicles toward programmable immune-priming approaches that integrate antigen quality, DC functional state, spatial organization, and tumor microenvironment features.
By integrating molecular vaccine design with tumor evolution, immune-contexture remodeling, and checkpoint sensitivity, this review identifies determinants that may distinguish successful immune priming from durable therapeutic efficacy and outlines priorities for biomarker-guided patient selection and future combinati...
T. Demircan, Berna Yıldırım, Halil İbrahim Ünsal et al.· International Journal of Mol...· 0 citations
Collectively, irradiation does not abrogate DC function, and anti-tumor immunity in radio-immunotherapy does not strictly require cDC1s, and anti-tumor immunity in radio-immunotherapy does not strictly require cDC1s.
Teresa Irianto, Ann-Sophie Flohr, C. Reichardt et al.· Oncoimmunology· 0 citations
Personalized cancer vaccines show great promise in targeting tumors with immunity; however, obstacles to their widespread use in clinical practice remain, including difficulties in identifying neoantigens, slow antigen clearance, and inadequate removal of tumor cells expressing the antigen. Here, we present a hydrogel...
Xiao-Ya Wang, Da-Xiu Deng, Yi-Xi He et al.· International Immunopharmaco...· 0 citations
Oncolytic viruses (OVs) are increasingly viewed not only as tumor-lysing agents but also as immunotherapeutic platforms capable of functioning as in situ cancer vaccines. By selectively infecting malignant cells, inducing immunogenic cell death, releasing tumor-associated antigens and danger signals, and activating inn...
Kamil Rogalski, Michał Iwaszko, Anna Kuraś et al.· Microorganisms· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.